27602763|t|Expressions of CD8 + TILs, PD-L1 and Foxp3 + TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
27602763|a|Currently, adjuvant chemotherapy is recommended for patients with high risk stage I non-small cell lung cancer (NSCLC). However, identifying high risk patients remains a challenge. This study aims to identify the patient cohorts more likely to benefit from adjuvant chemotherapy based on the tumor micro-immune environment. CD8 + TILs significantly associated with disease-free survival (DFS) and overall survial (OS) (p=0.002; 0.040). Patients with high risk factors may also predict shorter DFS (P=0.056). When compared together, patients with high - CD8 + TILs showed better DFS than patients with low - CD8 + TILs, no matter their risk factors status. There's no correlation between PD-L1 expressions and survival. PD-L1 was highly expressed in men, squamous and well differentiated carcinoma. In addition, Foxp3 + TILs alone didn't show any prognostic effects, but low - Foxp3 / high - CD8 + TILs were associated with prolonged DFS (p=0.031). A total of 126 patients with surgically resected stage I NSCLC were included to perform immunohistochemistry of CD8 + tumor infiltrating lymphocytes (TILs), programmed death ligand-1 (PD-L1) and forkhead box P3 (Foxp3)+ TILs. CD8 + TILs are effective prognostic predictors. Patients with surgically resected stage I NSCLC showing low CD8 + TILs could be considered for adjuvant chemotherapy, even if they have no high risk features.
27602763	0	11	Expressions	T045	C1171362
27602763	15	18	CD8	T129	C0085358
27602763	21	25	TILs	T025	C0079722
27602763	27	32	PD-L1	T116,T129	C0965245
27602763	37	42	Foxp3	T116,T123	C1504797
27602763	45	49	TILs	T025	C0079722
27602763	53	66	stage I NSCLC	T191	C0278504
27602763	75	96	adjuvant chemotherapy	T061	C0085533
27602763	97	106	decisions	T041	C0679006
27602763	118	139	adjuvant chemotherapy	T061	C0085533
27602763	143	154	recommended	T078	C0034866
27602763	159	167	patients	T101	C0030705
27602763	173	182	high risk	T033	C0332167
27602763	183	217	stage I non-small cell lung cancer	T191	C0278504
27602763	219	224	NSCLC	T191	C0007131
27602763	236	247	identifying	T080	C0205396
27602763	248	257	high risk	T033	C0332167
27602763	258	266	patients	T101	C0030705
27602763	293	298	study	T062	C2603343
27602763	299	303	aims	T078	C1947946
27602763	307	315	identify	T080	C0205396
27602763	320	327	patient	T101	C0030705
27602763	328	335	cohorts	T098	C0599755
27602763	364	385	adjuvant chemotherapy	T061	C0085533
27602763	399	404	tumor	T191	C0027651
27602763	405	417	micro-immune	T169	C0439662
27602763	418	429	environment	T082	C0014406
27602763	431	434	CD8	T129	C0085358
27602763	437	441	TILs	T025	C0079722
27602763	442	471	significantly associated with	T080	C0332281
27602763	472	493	disease-free survival	T081	C0242793
27602763	495	498	DFS	T081	C0242793
27602763	504	519	overall survial	T081	C4086681
27602763	521	523	OS	T081	C4086681
27602763	543	551	Patients	T101	C0030705
27602763	557	574	high risk factors	T033	C1830377
27602763	600	603	DFS	T081	C0242793
27602763	620	628	compared	T052	C1707455
27602763	639	647	patients	T101	C0030705
27602763	653	657	high	T080	C0205250
27602763	660	663	CD8	T129	C0085358
27602763	666	670	TILs	T025	C0079722
27602763	685	688	DFS	T081	C0242793
27602763	694	702	patients	T101	C0030705
27602763	708	711	low	T080	C0205251
27602763	714	717	CD8	T129	C0085358
27602763	720	724	TILs	T025	C0079722
27602763	742	754	risk factors	T033	C1830377
27602763	771	785	no correlation	T033	C0243095
27602763	794	799	PD-L1	T116,T129	C0965245
27602763	800	811	expressions	T045	C1171362
27602763	816	824	survival	T169	C0220921
27602763	826	831	PD-L1	T116,T129	C0965245
27602763	836	842	highly	T080	C0205250
27602763	843	852	expressed	T045	C1171362
27602763	856	859	men	T098	C0025266
27602763	861	869	squamous	T080	C1182670
27602763	874	893	well differentiated	T080	C0205615
27602763	894	903	carcinoma	T191	C0278504
27602763	918	923	Foxp3	T116,T123	C1504797
27602763	926	930	TILs	T025	C0079722
27602763	977	980	low	T080	C0205251
27602763	983	988	Foxp3	T116,T123	C1504797
27602763	991	995	high	T080	C0205250
27602763	998	1001	CD8	T129	C0085358
27602763	1004	1008	TILs	T025	C0079722
27602763	1014	1029	associated with	T080	C0332281
27602763	1030	1039	prolonged	T079	C0439590
27602763	1040	1043	DFS	T081	C0242793
27602763	1070	1078	patients	T101	C0030705
27602763	1084	1103	surgically resected	T080	C1521996
27602763	1104	1117	stage I NSCLC	T191	C0278504
27602763	1123	1131	included	T169	C0332257
27602763	1143	1163	immunohistochemistry	T060	C0021044
27602763	1167	1170	CD8	T129	C0085358
27602763	1173	1203	tumor infiltrating lymphocytes	T025	C0079722
27602763	1205	1209	TILs	T025	C0079722
27602763	1212	1237	programmed death ligand-1	T116,T129	C0965245
27602763	1239	1244	PD-L1	T116,T129	C0965245
27602763	1250	1265	forkhead box P3	T116,T123	C1504797
27602763	1267	1272	Foxp3	T116,T123	C1504797
27602763	1275	1279	TILs	T025	C0079722
27602763	1281	1284	CD8	T129	C0085358
27602763	1287	1291	TILs	T025	C0079722
27602763	1296	1305	effective	T080	C1704419
27602763	1329	1337	Patients	T101	C0030705
27602763	1343	1362	surgically resected	T080	C1521996
27602763	1363	1376	stage I NSCLC	T191	C0278504
27602763	1389	1392	CD8	T129	C0085358
27602763	1395	1399	TILs	T025	C0079722
27602763	1424	1445	adjuvant chemotherapy	T061	C0085533
27602763	1468	1477	high risk	T033	C0332167